Fully automated Individual Donation Nucleic Acid Amplification Technology (NAT) Testing System

Irish Blood Transfusion Service

A fully automated system for performing individual donation (ID) - Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150 000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing.
The ID-NAT Testing system will include testing reagents, consumables, equipment, operating software, servicing and maintenance.

Deadline

The time limit for receipt of tenders was 2017-05-12. The procurement was published on 2017-04-10.

Suppliers

The following suppliers are mentioned in award decisions or other procurement documents:

Who? What? Where?
Procurement history
Date Document
2017-04-10 Contract notice
2017-11-16 Contract award notice
Contract notice (2017-04-10)
Object
Scope of the procurement
Title: Blood-testing reagents
Reference number: IBTS/010/2017
Short description:
A fully automated system for performing individual donation (ID) - Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150 000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing. The ID-NAT Testing system will include testing reagents, consumables, equipment, operating software, servicing and maintenance.
Show more
Notice metadata
Original language: English ๐Ÿ—ฃ๏ธ
Document type: Contract notice
Nature of contract: Supplies
Regulation: European Union, with participation of GPA countries
Common procurement vocabulary (CPV)
Code: Blood-testing reagents ๐Ÿ“ฆ
Additional CPV: Laboratory reagents ๐Ÿ“ฆ
Place of performance
NUTS region: ร‰ire/Ireland ๐Ÿ™๏ธ

Procedure
Procedure type: Open procedure
Type of bid: Submission for all lots
Award criteria
The most economic tender

Contracting authority
Identity
Country: Ireland ๐Ÿ‡ฎ๐Ÿ‡ช
Awarding authority type: Body governed by public law
Awarding authority name: Irish Blood Transfusion Service
Postal address: National Blood Centre, James's Street
Postal code: D08 NH5R
Postal town: Dublin
Contact
Internet address: http://www.giveblood.ie ๐ŸŒ
E-mail: paul.behan@ibts.ie ๐Ÿ“ง
Phone: +353 14322846 ๐Ÿ“ž
URL for documents: http://irl.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=111040&B=ETENDERS_SIMPLE ๐ŸŒ
URL for participation: http://irl.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=111040&B=ETENDERS_SIMPLE ๐ŸŒ

Reference
Dates
Date dispatched: 2017-04-10 ๐Ÿ“…
Submission deadline: 2017-05-12 ๐Ÿ“…
Publication date: 2017-04-12 ๐Ÿ“…
Identifiers
Notice number: 2017/S 072-136779
OJ-S issue: 72
Additional information
The effective contract start date will be from successful validation of equipment and consumables.

Object
Scope of the procurement
Short description:
A fully automated system for performing individual donation (ID) - Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150 000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing.
Show more
The ID-NAT Testing system will include testing reagents, consumables, equipment, operating software, servicing and maintenance.
Estimated total value: 7 400 000 EUR ๐Ÿ’ฐ
Short description:
A fully automated system for performing individual donation (ID)- Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150 000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing.
Show more
Estimated value excluding VAT: 7 400 000 EUR ๐Ÿ’ฐ
Duration: 48 months
Description of renewals: The IBTS reserves the right to extend the contract for 12 months.
Additional information:
The effective contract start date will be from successful validation of equipment and consumables.

Legal, economic, financial and technical information
Conditions for participation
Suitability to pursue the professional activity: As per RFT.
Economic and financial standing: As per RFT.
Technical and professional ability: As per RFT.
Minimum level(s) of standards: As per RFT.

Procedure
Time of receipt of tenders: 12:00
Languages in which tenders or requests to participate may be submitted: English ๐Ÿ—ฃ๏ธ
Tender validity period: 2017-08-25 ๐Ÿ“…
Tender opening date: 2017-05-12 ๐Ÿ“…
Tender opening time: 12:00
Place: Electronic postbox.

Contracting authority
Identity
National registration number: N/a
Contact
Contact point: Paul Behan
Address of the buyer profile: https://irl.eu-supply.com/ctm/Company/CompanyInformation/Index/1186 ๐ŸŒ
Documents URL: http://irl.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=111040&B=ETENDERS_SIMPLE ๐ŸŒ

Complementary information
Review body
Name: Remedies Directive applies
Postal town: Dublin
Country: Ireland ๐Ÿ‡ฎ๐Ÿ‡ช
Body responsible for mediation procedures
Same as: Review body
Source: OJS 2017/S 072-136779 (2017-04-10)
Contract award notice (2017-11-16)
Object
Scope of the procurement
Short description:
A fully automated system for performing individual donation (ID)- Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150,000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing. The ID-NAT Testing system will include testing reagents, consumables, equipment, operating software, servicing and maintenance.
Show more
Total value of the procurement: 7 485 000 EUR ๐Ÿ’ฐ
Notice metadata
Document type: Contract award notice

Procedure
Type of bid: Not applicable

Reference
Dates
Date dispatched: 2017-11-16 ๐Ÿ“…
Publication date: 2017-11-18 ๐Ÿ“…
Identifiers
Notice number: 2017/S 222-461282
Refers to notice: 2017/S 072-136779
OJ-S issue: 222

Object
Scope of the procurement
Short description:
A fully automated system for performing individual donation (ID)- Nucleic Acid Amplification Technology (NAT) testing of IBTS donations in human plasma. The NAT laboratory currently tests approximately 150,000 donations/samples annually. HIV RNA, HCV RNA and HBV DNA NAT testing of IBTS donations and samples in individual donation format. In addition, the system must perform ID-NAT testing for Hepatitis E virus (HEV) and West Nile Virus (WNV) RNA, and future capability for NAT testing of additional viral markers on the proposed system testing platform e.g. Zika virus testing.
Show more
Description of options: Option to extend Contract for 12 months.

Procedure
Award criteria
Quality criterion (name): Compliance with User Requirement Specification
Quality criterion (weighting): 14
Cost criterion: Cost
Cost weighting: 6

Award of contract
Date of contract conclusion: 2017-11-13 ๐Ÿ“…
Source: OJS 2017/S 222-461282 (2017-11-16)